Member Info for Timber1234

Apologies. It is a Poolbeg webinar with Jeremy Skillington on the 8th not Hvivo.

Put questions to Mo at the LSE webinar on Nov. 8
Questions can be emailed to donald.leggat@lse.co.uk

How can 20m+ shares be bought without it effecting the share price?
£1m worth of shares were bought in one transaction within the the last 2-3 months and that didn’t effect the share price either.

Why? How?

Moni - I can’t find recordings of it at the moment.
Hvivo site states “The live broadcast has now finished. Please come back for the archive recording (if made available)”
I don’t see why it wouldn’t be made available.
I’ll email Walbrook.

I submitted a question re. CF’s continued commitment to Hvivo for the Capital Markets Day webcast which was at 09:30 this morning. I was unable to watch but hopefully a recording will be made available. Did anyone watch?

The BoD confirming their proactive efforts to attract II’s and increase exposure in the markets. I’m sure Mo, Stephen Pinkerton and Prof. Openshaw will deliver a compelling presentation.

Feels like the beginning of turning tide.

Thanks Hotchip. Another vote of confidence from experienced investors who understand the markets and recognise the huge potential of both ORPH and POLB.

Moni - Exactly. Aside from macro market forces, traders and the impatient , I’m sure the sp is still suffering from the last remaining covid ‘tourist investors’ selling without doing any research.

Strictly - I am down 75% on a six figure investment (£) beginning with a 2; but maintain faith and agree the tide will turn on the sp of this healthy, unique company with huge potential.

https://********.com/posts/8170182-mark-kenny-doc-discuss-the-markets-a-few-stocks

Insert ‘audioboom’
POLB - 27.25
ORPH - 24:32

https://*******.com/posts/8170182-mark-kenny-doc-discuss-the-markets-a-few-stocks

Insert ‘audioboom’
ORPH - 24:32

As the holder of a significant amount (£200k+) of ORPH shares I have decided to experience FluCamp for myself. I had my first assessment in Manchester last week, which involved giving a blood sample which will be screened for antibodies to determine my eligibility for challenge studies.

The process of signing up via the website was straightforward and user friendly. There were a couple of points which I thought could be approved upon and emailed my observations to Louis Ashe-Jepson at Walbrook. He replied promptly, thanked me and confirmed my comments would be forwarded to the company - I will revisit in a few weeks to check if my suggestions have been actioned.

The assessment itself was highly professional and the staff extremely helpful and friendly. I asked the nurse if they are busy and had a constant supply of volunteers - she replied they are “very busy” and “always have a supply of volunteers”. The clinic was pleasant and well equipped. Each volunteer is paid £40 to cover travel costs for the attending the initial assessment, which was transferred to my bank account within 48 hours. I will hear within the next 3-4 months whether I am eligible for challenge studies.

It has been a smooth process so far and certainly a worthwhile exercise. Volunteers are the lifeblood of challenge studies, so it is most reassuring the company is getting this right.

I will update this board if I am accepted onto a challenge study. Always useful to have feedback from ‘coal face,’ as it were.

Queen's University is hosting a conference this week on RSV with experts from around the world discussing developments in respiratory illnesses.

https://apple.news/ARzZC4ZMxQjub4kyZKH4i8A

Just have faith in the BoD. They know what they’re doing.

No one outside of the company knows what the BoD intend to do with the cash. For all we know they may have an acquisition planned. They know the company far more intimately than any retail investor does and I have faith in their experience, track record and ability to effectively run and expand the company.

Their interests are aligned with that of the shareholders, so whatever they have planned with the cash I have every confidence it will be the right decision. CF and Mo have significant skin in the game, so they obviously also want the share price to increase.

If, as an investor, one does not have faith in the BoD and feels they do not intend to act in the very best interest of their shareholders then it is most certainly time to sell.

Moni - nothing back from Walbrook either. I have just chased Louis Ashe-Jepson. Will keep you updated.

They’re responsiveness is admittedly inconsistent. But in their defence, they have responded promptly to various emails I have sent regarding serious matters. However, at other times not so prompt. The pattern hasn’t seemed to be related to the subject matter.

I have also just emailed Louis at Walbrook asking for comment regarding the article and what it implies for ORPH.

Response from Walbrook:

Hi *****,

Thanks for your email. The Company is aware of the media report relating to the allegation of an incident of potential insider dealing in the Company’s shares by an unconnected private individual in 2020.

The Company confirms that it was made aware of this allegation by, and at their request, is helping the relevant Irish authorities in respect of this allegation.

The Board of Open Orphan is satisfied that there are no implications for the Company in the resolution of this allegation and confirms that no employee, executive, director or anyone connected with the Company had any involvement whatsoever in this matter nor are they suspected of any wrongdoing.

Kind regards,
Louis

I have emailed Louis Ashe-Jepson at Walbrook, and ORPH directly, for confirmation the article is not in any way related to ORPH.

Exactly Steveo. It couldn’t be more transparent. Too many nervous, novice PI’s in this stock unfortunately. ORPH is in rude health but that’s meaningless for the SP gazers out for a quick buck who don’t look beyond the SP, or beyond the next 2-3 years for that matter.